[The clinical significance of CD(4)(+)CD(69)(+) T lymphocytes in patients with autoimmune hemolytic anemia/Evans syndrome]
- PMID: 30180450
- DOI: 10.3760/cma.j.issn.0578-1426.2018.09.007
[The clinical significance of CD(4)(+)CD(69)(+) T lymphocytes in patients with autoimmune hemolytic anemia/Evans syndrome]
Abstract
Objective: To investigate the significant of peripheral CD(4)(+) CD(69)(+) T lymphocytes in patients with autoimmune hemolytic anemia (AIHA)/Evans syndrome (ES). Methods: In this study peripheral blood samples from 32 patients with AIHA/ES (15 hemolytic episode patients, 17 remission patients) and 13 healthy controls were collected. Patients with AIHA/ES were recruited in Tianjin Medical University General Hospital from October 2015 to May 2016. The percentages of CD(69)(+) T lymphocytes were analyzed by flow cytometry. The expression of CD(69) mRNA in CD(4)(+) T lymphocytes which was sorted from peripheral blood by magnetic activated cell sorting (MACS) was detected using real-time PCR. Soluable CD(69) was measured by ELISA. Results: In hemolytic episode patients, the ratio of CD(3)(+)CD(69)(+)/CD(3)(+)T lymphocytes [(3.08±1.48)%] was significantly higher than that in healthy controls [(1.28±0.83)%, P<0.01] and in remission group[(1.96±1.33)%, P<0.05]. The absolute count of CD(3)(+)CD(69)(+)T lymphocytes in hemolytic episode group [(2.94±1.81)×10(7)/L] was higher than that in healthy controls [(1.48±1.42)×10(7)/L, P<0.05]. The ratio of CD(3)(+)CD(4)(+)CD(69)(+)/CD(3)(+)CD(4)(+)T cells in hemolytic episode group [(2.16±1.56)%] was significantly higher than that in remission group [(1.16±0.62)%, P<0.05] and healthy controls[(0.94±0.78)%, P<0.05]. The quantity of CD(3)(+)CD(4)(+)CD(69)(+)T lymphocytes in hemolytic episode group[(1.04±0.98)×10(7)/L] was higher than in healthy controls [(0.44±0.38)×10(7)/L, P<0.05]. The ratio of CD(3)(+)CD(8)(+)CD(69)(+)/CD(3)(+)CD(8)(+)T lymphocyte in hemolytic episode group [(4.87±2.56)%] was significantly higher than that in healthy controls[(1.83±1.27)%, P<0.01]. The quantity of CD(3)(+)CD(8)(+)CD(69)(+)T lymphocytes in three groups did not show significant difference. The ratio of CD(3)(+)CD(4)(+)CD(69)(+)/CD(3)(+)CD(4)(+) T lymphocytes in hemolytic episode group was negatively correlated with hemoglobin (Hb) (P<0.01) , positively correlated with the percentage of reticulocytes (Ret%) (P=0.01) total bilirubin(TBil), indirect bilirubin(IBil) (P<0.01) and not correlated with absolute reticulocytes count, lactic dehydrogenase (LDH), complement 3(C3), complement 4 (C4). The ratio of CD(3)(+)CD(4)(+)CD(69)(+)/CD(3)(+)CD(4)(+)T lymphocytes in remission group was negatively correlated with Hb (P<0.05). In hemolytic episode patients CD(69) mRNA (32.26±35.11) was significantly higher than that in remission group(6.05±5.87) (P<0.05) and healthy controls (1.76±1.85)(P<0.01). CD(69) mRNA in remission group was significantly higher than healthy controls (P<0.05). Serum CD(69) in hemolytic episode patients [(494.21±16.06) ng/L] was significantly higher than that in healthy controls [(441.39±104.6) ng/L, P<0.05]. Conclusion: Our findings suggest that the proportion of CD(4)(+)CD(69)(+) T lymphocytes increase in AIHA/ES patients, which is correlated with the severity of disease.
目的: 了解自身免疫性溶血性贫血(AIHA)/Evans综合征(ES)患者外周血CD(4)(+)CD(69)(+)T细胞的临床意义。 方法: 选取2015年10月至2016年5月于天津医科大学总医院血液科住院的AIHA/ES患者32例,其中溶血发作组15例,缓解组17例;健康对照13名。以流式细胞仪检测外周血CD(69)(+)T细胞;实时定量PCR检测外周血CD(4)(+)T细胞中CD(69) mRNA表达水平;酶联免疫吸附试验(ELISA)检测血浆CD(69)浓度。 结果: (1)溶血发作组的CD(3)(+)CD(69)(+)/CD(3)(+) T细胞比例高于缓解组[(3.08±1.48)%比(1.96±1.33)%, P<0.05]和健康对照组[(1.28±0.83)%, P<0.01];溶血发作组CD(3)(+)CD(69)(+)T细胞绝对值高于健康对照组[(2.94±1.81)×10(7)/L比(1.48±1.42)×10(7)/L, P<0.05]。(2)溶血发作组CD(3)(+)CD(4)(+)CD(69)(+)/CD(3)(+)CD(4)(+) T细胞比例高于缓解组[(2.16±1.56)%比(1.16±0.62)%,P<0.05]及健康对照组[(0.94±0.78)%,P<0.05];溶血发作组CD(3)(+)CD(4)(+)CD(69)(+)T细胞绝对值高于健康对照组[(1.04±0.98)×10(7)/L比(0.44±0.38)×10(7)/L,P<0.05]。(3)溶血发作组CD(3)(+)CD(8)(+)CD(69)(+)/CD(3)(+)CD(8)(+) T细胞比例高于健康对照组[(4.87±2.56)%比(1.83±1.27)%,P<0.01];但CD(3)(+)CD(8)(+)CD(69)(+) T细胞绝对值在3组间差异无统计学意义。(4)Pearson相关分析显示,溶血发作组CD(3)(+)CD(4)(+)CD(69)(+)/CD(3)(+)CD(4)(+) T细胞比例与血红蛋白浓度呈负相关(P<0.01),与总胆红素以及间接胆红素均呈正相关(P均<0.01),与网织红细胞比例呈正相关(P=0.01);缓解组CD(3)(+)CD(4)(+)CD(69)(+)/CD(3)(+)CD(4)(+) T细胞比例与血红蛋白浓度呈负相关(P<0.05)。(5)溶血发作组CD(4)(+) T细胞中CD(69) mRNA的相对表达水平显著高于缓解组(32.26±35.11比6.05±5.87,P<0.05)及健康对照组(1.76±1.85,P<0.01),缓解组高于健康对照组(P<0.05)。(6)溶血发作组患者血浆CD(69)水平高于健康对照组[(494.21±16.06) ng/L比(441.39±104.6) ng/L,P<0.05]。 结论: AIHA/ES患者外周血CD(69)(+) T细胞比例增高,以CD(4)(+)CD(69)(+) T细胞增高为主,且与AIHA/ES的疾病严重程度相关。.
Keywords: Anemia, hemolytic, autoimmune; Antigens, CD(69); CD(4)-positive T-lymphocytes.
Similar articles
-
miR-150 regulates B lymphocyte in autoimmune hemolytic anemia/Evans syndrome by c-Myb.Int J Hematol. 2018 Jun;107(6):666-672. doi: 10.1007/s12185-018-2429-z. Epub 2018 Feb 27. Int J Hematol. 2018. PMID: 29488168
-
CD5+ B lymphocytes secrete IL-10 rather than TGF-β1 which control the immune response in autoimmune haemolytic anaemia/Evans syndrome.Autoimmunity. 2019 Feb;52(1):12-20. doi: 10.1080/08916934.2019.1576644. Epub 2019 Feb 20. Autoimmunity. 2019. PMID: 30784322 Clinical Trial.
-
Expression of activated molecules on CD5(+)B lymphocytes in autoimmune hemolytic anemia.Int J Hematol. 2016 May;103(5):545-53. doi: 10.1007/s12185-016-1964-8. Epub 2016 Mar 11. Int J Hematol. 2016. PMID: 26968550
-
Efficacy of therapeutic plasma exchange for treatment of autoimmune hemolytic anemia: A systematic review and meta-analysis of randomized controlled trials.J Clin Apher. 2020 Aug;35(4):294-306. doi: 10.1002/jca.21790. Epub 2020 May 8. J Clin Apher. 2020. PMID: 32384203
-
Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.Biomed Res Int. 2015;2015:363278. doi: 10.1155/2015/363278. Epub 2015 Jan 29. Biomed Res Int. 2015. PMID: 25705656 Free PMC article. Review.
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous